31 May Tiragolumab (TIGIT inhibitor) plus Atezolizumab shows promising Efficacy in PD-L1-positive advanced NSCLC
In chemotherapy-naïve, PD-L1-positive (tumour proportion score ≥1%) patients with locally advanced or metastatic NSCLC, tiragolumab plus atezolizumab showed a significant improvement in both objective response rate (ORR) and progression-free survival (PFS), with a stratified hazard ratio 0·57 [95% CI 0·37–0·90], p=0·015.
The combination was well tolerated, with a safety profile similar to that of atezolizumab alone. (Cho BC et al. The lancet Oncology May 13, 2022)